BioTelemetry (BEAT) : Globeflex Capital L P scooped up 44 additional shares in BioTelemetry during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 127,147 shares of BioTelemetry which is valued at $2,653,558.BioTelemetry makes up approximately 0.68% of Globeflex Capital L P’s portfolio.
Other Hedge Funds, Including , Dynamic Technology Lab Private Ltd reduced its stake in BEAT by selling 12,723 shares or 51.22% in the most recent quarter. The Hedge Fund company now holds 12,117 shares of BEAT which is valued at $252,882. BioTelemetry makes up approx 0.06% of Dynamic Technology Lab Private Ltd’s portfolio.Acrospire Investment Management boosted its stake in BEAT in the latest quarter, The investment management firm added 4,900 additional shares and now holds a total of 8,214 shares of BioTelemetry which is valued at $172,165. BioTelemetry makes up approx 0.12% of Acrospire Investment Management’s portfolio.Alambic Investment Management boosted its stake in BEAT in the latest quarter, The investment management firm added 18,405 additional shares and now holds a total of 46,705 shares of BioTelemetry which is valued at $976,602. BioTelemetry makes up approx 0.22% of Alambic Investment Management’s portfolio. Airain Ltd added BEAT to its portfolio by purchasing 25,762 company shares during the most recent quarter which is valued at $538,941. BioTelemetry makes up approx 0.03% of Airain Ltd’s portfolio.
BioTelemetry closed down -0.19 points or -0.89% at $21.11 with 3,39,093 shares getting traded on Friday. Post opening the session at $21.2, the shares hit an intraday low of $20.52 and an intraday high of $21.23 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.17. The company had revenue of $52.68 million for the quarter, compared to analysts expectations of $50.27 million. The company’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS.
Many Wall Street Analysts have commented on BioTelemetry. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $20 .